Tower Bridge Advisors’s AbbVie ABBV Stock Holding History

Tower Bridge Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.55M	Sell	39,323 -700	-2%	-$155K	0.83%	38
2025 Q4	$9.14M	Sell	40,023 -82	-0.2%	-$18.7K	0.92%	32
2025 Q3	$9.29M	Sell	40,105 -13	-0%	-$2.65K	0.93%	33
2025 Q2	$7.45M	Buy	40,118 +140	+0.4%	+$26K	0.8%	38
2025 Q1	$8.38M	Sell	39,978 -100	-0.2%	-$19.4K	0.94%	38
2024 Q4	$7.12M	Buy	40,078 +75	+0.2%	+$13.8K	0.76%	42
2024 Q3	$7.9M	Buy	40,003 +1,900	+5%	+$355K	0.82%	39
2024 Q2	$6.54M	Hold	38,103	–	–	0.73%	42
2024 Q1	$6.94M	Sell	38,103 -3,583	-9%	-$618K	0.71%	45
2023 Q4	$6.46M	Sell	41,686 -152	-0.4%	-$22.2K	0.56%	55
2023 Q3	$6.24M	Buy	41,838 +287	+0.7%	+$42.1K	0.58%	55
2023 Q2	$5.6M	Sell	41,551 -13,848	-25%	-$2.03M	0.51%	58
2023 Q1	$8.83M	Sell	55,399 -980	-2%	-$150K	0.72%	39
2022 Q4	$9.11M	Sell	56,379 -300	-0.5%	-$46K	0.76%	36
2022 Q3	$7.61M	Sell	56,679 -1,549	-3%	-$222K	0.68%	46
2022 Q2	$8.92M	Sell	58,228 -3,821	-6%	-$584K	0.73%	42
2022 Q1	$10.1M	Buy	62,049 +1,700	+3%	+$247K	0.67%	47
2021 Q4	$8.17M	Sell	60,349 -3,937	-6%	-$465K	0.5%	64
2021 Q3	$6.93M	Buy	64,286 +2,432	+4%	+$278K	0.46%	66
2021 Q2	$6.97M	Buy	61,854 +4,440	+8%	+$500K	0.46%	66
2021 Q1	$6.21M	Buy	57,414 +3,727	+7%	+$399K	0.47%	69
2020 Q4	$5.75M	Buy	53,687 +26,365	+96%	+$2.53M	0.47%	62
2020 Q3	$2.39M	Buy	27,322 +90	+0.3%	+$8.47K	0.24%	86
2020 Q2	$2.67M	Sell	27,232 -70	-0.3%	-$6.16K	0.3%	75
2020 Q1	$2.08M	Sell	27,302 -180	-0.7%	-$15.3K	0.27%	81
2019 Q4	$2.43M	Buy	27,482 +350	+1%	+$29.1K	0.26%	91
2019 Q3	$2.31M	Sell	27,132 -4,850	-15%	-$333K	0.25%	93
2019 Q2	$2.33M	Sell	31,982 -400	-1%	-$31.4K	0.26%	88
2019 Q1	$2.61M	Buy	32,382 +4,031	+14%	+$330K	0.3%	79
2018 Q4	$2.61M	Sell	28,351 -1,550	-5%	-$136K	0.34%	76
2018 Q3	$2.83M	Sell	29,901 -1,444	-5%	-$137K	0.3%	87
2018 Q2	$2.9M	Sell	31,345 -401	-1%	-$39.2K	0.32%	85
2018 Q1	$3M	Sell	31,746 -3,387	-10%	-$372K	0.33%	81
2017 Q4	$3.4M	Buy	35,133 +40	+0.1%	+$3.77K	0.36%	75
2017 Q3	$3.12M	Sell	35,093 -1,021	-3%	-$77.7K	0.35%	75
2017 Q2	$2.62M	Sell	36,114 -2,298	-6%	-$154K	0.3%	84
2017 Q1	$2.5M	Sell	38,412 -200	-0.5%	-$12.6K	0.29%	87
2016 Q4	$2.42M	Sell	38,612 -2,782	-7%	-$170K	0.29%	83
2016 Q3	$2.61M	Sell	41,394 -211	-0.5%	-$13.7K	0.32%	85
2016 Q2	$2.58M	Hold	41,605	–	–	0.32%	84
2016 Q1	$2.38M	Sell	41,605 -100	-0.2%	-$5.57K	0.3%	86
2015 Q4	$2.47M	Hold	41,705	–	–	0.32%	81
2015 Q3	$2.27M	Buy	41,705 +300	+0.7%	+$19.5K	0.31%	81
2015 Q2	$2.78M	Sell	41,405 -366	-0.9%	-$23.9K	0.35%	76
2015 Q1	$2.45M	Buy	41,771 +231	+0.6%	+$14K	0.31%	82
2014 Q4	$2.72M	Sell	41,540 -500	-1%	-$31.5K	0.33%	78
2014 Q3	$2.43M	Sell	42,040 -160	-0.4%	-$8.88K	0.31%	80
2014 Q2	$2.38M	Sell	42,200 -3,700	-8%	-$194K	0.29%	81
2014 Q1	$2.36M	Sell	45,900 -6,733	-13%	-$340K	0.3%	79
2013 Q4	$2.78M	Sell	52,633 -1,513	-3%	-$74.4K	0.36%	71
2013 Q3	$2.42M	Buy	54,146 +350	+0.7%	+$15.5K	0.35%	73
2013 Q2	$2.22M	Buy	+53,796	New	+$2.35M	0.33%	74

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tower Bridge Advisors's ABBV Position: Q1 2026 in Review

Tower Bridge Advisors reduced its AbbVie (ABBV) stake by 1.7% in Q1 2026, selling an estimated $155K and leaving 39,323 shares worth $8.55M. The position accounts for 0.83% of the portfolio, ranked #38.

Tower Bridge Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.1M in Q1 2022. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Tower Bridge Advisors held 39,323 shares of AbbVie worth $8.55M as of Q1 2026.
Tower Bridge Advisors sold 700 AbbVie shares in Q1 2026, an estimated $155K.
AbbVie made up 0.83% of Tower Bridge Advisors's portfolio in Q1 2026, its #38 holding.
Tower Bridge Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Tower Bridge Advisors's AbbVie position peaked at $10.1M in Q1 2022.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Tower Bridge Advisors's 13F filing for Q1 2026, filed 12 May 2026.